

Author Index

BR: Book review
CR: Conference report

A

- Albuquerque, E.X., *see* Maelicke, A. 53
Arnold, R. and Grindley, J., Matchmaking: identifying and evaluating drug discovery partners 79
Ashton, M.J., Jaye, M. and Mason, J.S., New perspectives in lead generation I: Discovery of biological targets 11
Ashton, M.J., Jaye, M.C. and Mason, J.S., New perspectives in lead generation II: Evaluating molecular diversity 71

B

- Bailey, D. and Mackay, M., Genome revolution: impact on drug discovery and development 126
Beck-Sickinger, A., *G Protein-Coupled Receptors* (BR) 9
Beck-Sickinger, A.G., Structural characterization and binding sites of G-protein-coupled receptors 502
Beckett, R.P., Davidson, A.H., Drummond, A.H., Huxley, P. and Whittaker, M., Recent advances in matrix metalloproteinase inhibitor research 16
Beeley, L.J. and Duckworth, D.M., The impact of genomics on drug design 474
Beusen, D.D. and Shands, E.F.B., Systematic search strategies in conformational analysis 429
Billington, D.C., Inhibition of angiogenesis as a potential therapeutic strategy 492
Binns, R., Challengeability of biotechnology patents in the light of Biogen v. Medeva 35
Boger, D., *Cancer Chemotherapeutic Agents* (BR) 46
Bohlin, L. and Rosén, B., Podophyllotoxin derivatives: drug discovery and development 343
Bondy, S., Cheng, S., Saunders, J., Tarby, C. and Wheeler, K., Molecular diversity and solid-phase synthesis (CR) 132
Boons, G.-J., Synthetic oligosaccharides: recent advances 331

- Bradley, D., Beating superbugs with the Gulliver effect 361
Bradley, D., Better use aspirin 49
Bradley, D., Taxol moves on 497
Breimer, D.D., University-industry collaboration in the pharmaceutical sciences 403
Brown, A.G., Bioprospecting for leads (CR) 270

C

- Carreira, E.M. and Singer, R.A., Advances in catalytic, enantioselective aldol addition reactions with novel Ti(IV) complexes 145
Carreira, E.M., *Classics in Total Synthesis: Targets, Strategies, Methods* (BR) 412
Cashman, J.R., Drug discovery and drug metabolism 209
Cavalla, D., Devolved drug discovery and the virtual research centre 87
Chan, O.H. and Stewart, B.H., Physicochemical and drug-delivery considerations for oral drug bioavailability 461
Chaturvedi, P.R., *see* Navia, M.A. 179
Cheng, S., *see* Bondy, S. 132
Choi, T.D., *see* Lutz, M.W. 277
Cliffe, I.A., *see* Palmer, A.M. 456
Colacino, J.M. and Laver, W.G., Antivirals for influenza infection (CR) 359
Cook, N.D., Scintillation proximity assay: a versatile high-throughput screening technology 287
Cooper, M.S., *see* Stevens, M.F.G. 401

D

- Davidson, A.H., *see* Beckett, R.P. 16
Dell, C.P., Therapeutic profile: Diabetic complications 221
Doherty, A.M., Design and discovery of nonpeptide endothelin antagonists 60
Domanico, P.L., *see* Lutz, M.W. 277
Drummond, A.H., *see* Beckett, R.P. 16
Duckworth, D.M., *see* Beeley, L.J. 474
Duplantier, A.J. and Turner, C.R., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes 199

E

- Eaton, B.E., *Carbohydrate Modifications in Antisense Research* (BR) 230

F

- Fattom, A., *see* Sood, R.K. 381
Finn, P.W., Computer-based screening of compound databases for the identification of novel leads 363

G

- Gard, P.R., Angiotensin in psychiatry – a possible role 536
Gasparini, F., *see* Knöpfel, T. 103
Giordano, C., Society for Biomolecular Screening 93
Goetz, A.S., *see* Lutz, M.W. 277
Gooding Laskody, R., *see* Lutz, M.W. 277
Gordon, E.M., *see* Patel, D.V. 134
Grindley, J., *see* Arnold, R. 79

H

- Heavner, G.A., Active sequences in cell adhesion molecules: targets for therapeutic intervention 295
Heering, J.M., Protein kinase C links to cancer 492
Heimbrook, D.C., *see* Patrick, D.R. 325
Hill, C.H. and Jones, P., *Emerging Drugs: The Prospect for Improved Medicines* (BR) 460
Hook, D., Ultra high-throughput screening – a journey into Nanoland with Gulliver and Alice 267
Hu, H., Recent discovery and development of selective protein kinase C inhibitors 438
Hughes, D., CAS record 52
Hughes, D., Cerebrus – contract CNS discovery research 176
Hughes, D., Controlling proliferation through collaboration 404
Hughes, D., Devolved drug discovery – the story continues 88
Hughes, D., *Drug Discovery Today and the status quo* 1
Hughes, D., Expansion at Oxford Asymmetry 274

- Hughes, D., Gonal-F® gains first centralized approval from EMEA 2
- Hughes, D., ISLAR '95: 'More for less' 7
- Hughes, D., NIH patent profile 92
- Hughes, D., Novartis who? An update 228
- Hunter, P.A., Focus on fungal infections 227
- Huxley, P., *see* Beckett, R.P. 16
- J**
- Jack, D.B., A pharmaceutical Braveheart – battle lines are drawn 48
- Jack, D.B., Cardiovascular trials update 269
- Jack, D.B., Drug companies on the Net 130
- Jack, D.B., Furberg goes over the top on calcium channel antagonists 225
- Jack, D.B., Live dangerously – eat something 315
- Jack, D.B., New Alzheimer's model from Japan 49
- Jack, D.B., Novartis who? 176
- Jack, D.B., People 4, 52
- Jack, D.B., Scots search for slimmers' holy grail 226
- Jack, D.B., Swedish scientist honoured for Turbohaler 133
- Jaye, M., *see* Ashton, M.J. 11
- Jaye, M.C., *see* Ashton, M.J. 71
- Johnson, G., What place for R&D in tomorrow's drug industry? 117
- Jones, P., *see* Hill, C.H. 460
- K**
- Kerr, D.I.B. and Ong, J., GABA_B receptors: targets for drug development 371
- Kilpatrick, M., *Ways to Successful Strategies in Drug Research and Development* (BR) 501
- King, F.D., *The Organic Chemistry of Drug Synthesis* Volume 5 (BR) 229
- Knöpfel, T. and Gasparini, F., Metabotropic glutamate receptors: potential drug targets 103
- Koganty, R.R., Reddish, M.A. and Longenecker, B.M., Glycopeptide- and carbohydrate-based synthetic vaccines for the immunotherapy of cancer 190
- Kozlowski, M.R., Problem-solving in laboratory automation 481
- Krystal, M.R., *see* Meanwell, N.A. 316
- Krystal, M.R., *see* Meanwell, N.A. 388
- L**
- Laver, W.G., *see* Colacino, J.M. 359
- Li, J., CAMD in modern drug discovery 311
- Lightfoot, G., Drug discovery and VDDCs 255
- Lloyd, A.W., Monitor 39, 82, 122, 169, 217, 261, 305, 352, 398, 448, 489, 533
- Lloyd, A.W., Case histories in drug discovery 90
- Lloyd, A.W., Corticotropin-releasing factors and Alzheimer's disease 127
- Lloyd, A.W., *see* Rhys-Williams, W. 7
- Longenecker, B.M., *see* Koganty, R.R. 190
- Lutz, M.W., Menius, J.A., Choi, T.D., Gooding Laskody, R., Domanico, P.L., Goetz, A.S. and Saussy, D.L., Experimental design for high-throughput screening 277
- M**
- Mackay, M., *see* Bailey, D. 126
- MacRitchie, H.B., Strategic use of drug delivery systems 406
- Maelicke, A. and Albuquerque, E.X., New approach to drug therapy in Alzheimer's dementia 53
- Manallack, D.T., Getting that hit: 3D database searching in drug discovery 231
- Manning, A.M., Transcription factors: a new frontier for drug discovery 151
- Marr, J.J., Ribozymes as therapeutic agents 94
- Marriott, C., Questioning models 175
- Martin, M.T., Commercially valuable catalytic antibodies: the life to come 239
- Mason, J.S., *see* Ashton, M.J. 11
- Mason, J.S., *see* Ashton, M.J. 71
- McLay, I.M., *Chemometric Methods in Molecular Design* (BR) 412
- Meanwell, N.A. and Krystal, M.R., Taking aim at a moving target – inhibitors of influenza virus Part 1: virus adsorption, entry and uncoating 316
- Meanwell, N.A. and Krystal, M.R., Taking aim at a moving target – inhibitors of influenza virus Part 2: viral replication, packaging and release 388
- Menius, J.A., *see* Lutz, M.W. 277
- Murcko, M.A., *Computer Modelling in Molecular Biology* (BR) 500
- Murcko, M.A., *QSAR: Hansch Analysis and Related Approaches* (BR) 362
- Murcko, M.A., Small-molecule mimetics (CR) 408
- N**
- Naso, R.B., *see* Sood, R.K. 381
- Navia, M.A. and Chaturvedi, P.R., Design principles for orally bioavailable drugs 179
- Nielsen, J., Combinatorial chemistry and automation (CR) 458
- O**
- Ong, J., *see* Kerr, D.I.B. 371
- P**
- Palmer, A.M. and Cliffe, I.A., Recent advances in the treatment of acute neurodegeneration (CR) 456
- Parrill, A.L., Evolutionary and genetic methods in drug design 514
- Patel, D.V. and Gordon, E.M., Applications of small-molecule combinatorial chemistry to drug discovery 134
- Patrick, D.R. and Heimbroke, D.C., Protein kinase inhibitors for the treatment of cancer 325
- Pavliak, V., *see* Sood, R.K. 381
- Potter, B.V.L., Woo, L.W.L., Purohit, A. and Reed, M.J., Steroid sulfatase inhibitors 308
- Prokai, L., Delivery of peptides into the central nervous system 161
- Purohit, A., *see* Potter, B.V.L. 308
- R**
- Reddish, M.A., *see* Koganty, R.R. 190
- Reed, M.J., *see* Potter, B.V.L. 308
- Rhys-Williams, W. and Lloyd, A.W., Chiral Europe '95 (CR) 7
- Rosén, B., *see* Bohlin, L. 343
- Ruscus, C., Intellectual property rights in biotechnology 453
- S**
- Sabin, V., XIVth International Symposium on Medicinal Chemistry (CR) 498
- Sainsbury, M., *Taxane Anticancer Drugs: Basic Science and Current Status* (BR) 131
- Saunders, J., *see* Bondy, S. 132
- Saussy, D.L., *see* Lutz, M.W. 277
- Savello, D.R., Speeding new medicines to patients 45

Shands, E.F.B., *see* Beusen, D.D. 429
 Simon, P.M., Pharmaceutical oligosaccharides 522
 Singer, R.A., *see* Carreira, E.M. 145
 Sofia, M.J., Generation of oligosaccharide and glycoconjugate libraries for drug discovery 27
 Sood, R.K., Fattom, A., Pavliak, V. and Naso, R.B., Capsular polysaccharide-protein conjugate vaccines 381
 Stevens, M.F.G., Cooper, M.S. and Westwell, A.D., L-Azatyrosine: a new lead in anticancer drug development 401
 Stewart, B.H., *see* Chan, O.H. 461
 Storer, R., Solution-phase synthesis in combinatorial chemistry: Applications in drug discovery 248
 Swain, C.J., Therapeutic profile: NK₁ receptor antagonists 265
 Szymkowski, D.E., Developing antisense oligonucleotides from the laboratory to clinical trials 415

T

Tarby, C., *see* Bondy, S. 132

Terrett, N., Combinatorial chemistry – the way forward 129
 Terrett, N., Combinatorial chemistry 222, 266, 308, 355, 402, 450, 493, 537
 Terrett, N., Video reviews – *Chemical Diversity: Synthetic Techniques of Combinatorial Chemistry* and *Chemical Diversity: Applications of Computational Approaches* 275
 Thorne, M., Maximizing the value of bioinformatics in drug discovery (CR) 272
 Thun, M.J., Do NSAIDs prevent colorectal cancer? 495
 Turner, C.R., *see* Duplantier, A.J. 199
 Turner, N.C., New therapeutic agents for the treatment of insulin resistance and NIDDM 109

W

Wallace, R.W., Automated lead discovery 46
 Wallace, R.W., Combinatorial biology 48
 Wallace, R.W., Cystic fibrosis: new strategies for drug therapy 225
 Wallace, R.W., Do mutated presenilin genes cause Alzheimer's? 453

Wallace, R.W., Emerging molecular targets 42, 85, 126, 173, 223, 264, 309, 355, 402, 450, 494, 538
 Wallace, R.W., Genomics at the AAAS 177
 Wallace, R.W., Green fluorescent protein – 'paint in a can' 496
 Wallace, R.W., Novel targets for drug discovery 91
 Wallace, R.W., Packard and Aurora Biosciences to codevelop ultra-HTS technologies 313
 Wallace, R.W., PDB funding 315
 Wallace, R.W., Pfizer natural products collaboration 4
 Wallace, R.W., Progesterone and myelin synthesis 5
 Wallace, R.W., Rapamycin 'glue strategy' 406
 Wallace, R.W., Transcriptional regulation: a risk worth taking? 357
 Wess, G., Challenges for medicinal chemistry 529
 Westwell, A.D., *see* Stevens, M.F.G. 401
 Wheeler, K., *see* Bondy, S. 132
 White, J.H., Modified transcriptional activators as therapeutic tools (CR) 50
 Whittaker, M., *see* Beckett, R.P. 16
 Woo, L.W.L., *see* Potter, B.V.L. 308